MDT

82.86

-5.69%ā†“

VEEV

213.67

-3.6%ā†“

A

100.51

-8.39%ā†“

HQY

76.5

-7.7%ā†“

PDCO

30.94

-0.83%ā†“

MDT

82.86

-5.69%ā†“

VEEV

213.67

-3.6%ā†“

A

100.51

-8.39%ā†“

HQY

76.5

-7.7%ā†“

PDCO

30.94

-0.83%ā†“

MDT

82.86

-5.69%ā†“

VEEV

213.67

-3.6%ā†“

A

100.51

-8.39%ā†“

HQY

76.5

-7.7%ā†“

PDCO

30.94

-0.83%ā†“

MDT

82.86

-5.69%ā†“

VEEV

213.67

-3.6%ā†“

A

100.51

-8.39%ā†“

HQY

76.5

-7.7%ā†“

PDCO

30.94

-0.83%ā†“

MDT

82.86

-5.69%ā†“

VEEV

213.67

-3.6%ā†“

A

100.51

-8.39%ā†“

HQY

76.5

-7.7%ā†“

PDCO

30.94

-0.83%ā†“

Search

GlycoMimetics Inc

Gesloten

SectorGezondheidszorg

0.17 -5.56

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.15

Max

0.19

Belangrijke statistieken

By Trading Economics

Inkomsten

2.6M

-7.2M

EPS

-0.112

Werknemers

4

EBITDA

399K

-5.3M

Dividenden

By Dow Jones

Volgende Winsten

8 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

13M

Vorige openingsprijs

5.73

Vorige sluitingsprijs

0.17

Nieuwssentiment

By Acuity

47%

53%

161 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

GlycoMimetics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 jul 2024, 15:11 UTC

Belangrijke Marktbewegers

GlycoMimetics Shares Drop 27% After Restructuring Plan, Job Cuts

Peer Vergelijking

Prijswijziging

GlycoMimetics Inc Prognose

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technische score

By Trading Central

N/A / 0.2097Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

161 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over GlycoMimetics Inc

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.